amsacrine has been researched along with Acute Myelogenous Leukemia in 159 studies
Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.
amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Amsacrine and high-dose cytarabine (HiDAc), when administered as single agents, are effective treatment of acute leukemia." | 9.06 | A new regimen of amsacrine with high-dose cytarabine is safe and effective therapy for acute leukemia. ( Ahmed, T; Arlin, ZA; Baskind, P; Feldman, E; Mehta, R; Mittelman, A; Rieber, E; Sullivan, P; Weinstein, P, 1987) |
| "Patients with acute myelogenous leukemia in relapse who were ineligible for further anthracycline therapy either because they were judged to be anthracycline resistant or had received the maximum doses were randomized to receive high-dose cytarabine (3 g/m2 every 12 hours for 6 days) or amsacrine (75 mg/m2 daily for 7 days)." | 9.06 | Randomized trial of high-dose cytarabine versus amsacrine in acute myelogenous leukemia in relapse: a Leukemia Intergroup Study. ( Brennan, J; Browman, G; Goldberg, J; Gottlieb, AJ; Grunwald, H; Miller, KB; Preisler, HD; Rai, K; Vogler, WR; Winton, EF, 1986) |
| "The role of amsacrine in inducing remission in patients with cardiac disease and acute leukemia was evaluated." | 7.68 | Amsacrine is safe and effective therapy for patients with myocardial dysfunction and acute leukemia. ( Ahmed, T; Arlin, ZA; Baskind, P; Chun, HG; Cook, P; Feldman, EJ; Marboe, C; Mehta, R; Mittelman, A; Puccio, C, 1991) |
| "We describe 2 patients in whom a sustained remission of longstanding rheumatoid arthritis occurred with treatment for acute myelogenous leukemia (cytosine arabinoside, daunorubicin, and m-AMSA), even though both illnesses had been refractory to therapy with standard disease-modifying agents." | 7.67 | Remission of rheumatoid arthritis with the successful treatment of acute myelogenous leukemia with cytosine arabinoside, daunorubicin, and m-AMSA. ( Jones, RJ; Karp, JE; Roubenoff, R; Stevens, MB, 1987) |
| "Twenty-six adults with refractory leukemia were treated with amsacrine gluconate, a new formulation." | 7.66 | Phase II study of amsacrine gluconate in refractory leukemia. ( Grillo-Lopez, AJ; Omura, GA; Vogler, WR; Winton, EF; Zuckerman, KS, 1983) |
| " In acute myelogenous leukemia, amsacrine is as effective as the two most active drugs, cytarabine and daunorubicin and can produce complete remissions in patients refractory to these drugs." | 6.15 | Amsacrine: a review. ( Cassileth, PA; Gale, RP, 1986) |
| "Amsacrine was also found to be highly bound to plasma proteins (96." | 5.27 | Pharmacokinetics of amsacrine in patients receiving combined chemotherapy for treatment of acute myelogenous leukemia. ( Jurlina, JL; Paxton, JW; Varcoe, AR, 1985) |
| "Forty-eight patients with acute myelogenous leukemia (AML) not eligible for anthracycline or mitoxantrone treatment, mostly due to cardiac contraindications, were given aggressive therapy using m-amsacrine (AMSA) in combination with conventional or high-dose cytarabine for remission induction." | 5.07 | AMSA combination chemotherapy in patients with acute myelogenous leukemia unsuitable for standard antileukemic treatment. ( Heit, W; Maschmeyer, G; Willborn, K, 1992) |
| "In a randomized trial, 299 evaluable patients with acute myelogenous leukemia, age greater than or equal to 51, were initially randomized to cytosine arabinoside, 100 mg/m2/day, by continuous intravenous infusion for seven days, plus either daunorubicin 45 mg/m2/day x 3 (DA), or m-AMSA 200 mg/m2/day x 3 days (MA)." | 5.06 | Therapy of acute myelogenous leukemia in patients over the age of 50: a randomized Southeastern Cancer Study Group trial. ( Bartolucci, A; Cohen, HJ; Raney, MR; Stein, RS; Vogler, WR; Winton, EF, 1990) |
| "Amsacrine and high-dose cytarabine (HiDAc), when administered as single agents, are effective treatment of acute leukemia." | 5.06 | A new regimen of amsacrine with high-dose cytarabine is safe and effective therapy for acute leukemia. ( Ahmed, T; Arlin, ZA; Baskind, P; Feldman, E; Mehta, R; Mittelman, A; Rieber, E; Sullivan, P; Weinstein, P, 1987) |
| "Patients with acute myelogenous leukemia in relapse who were ineligible for further anthracycline therapy either because they were judged to be anthracycline resistant or had received the maximum doses were randomized to receive high-dose cytarabine (3 g/m2 every 12 hours for 6 days) or amsacrine (75 mg/m2 daily for 7 days)." | 5.06 | Randomized trial of high-dose cytarabine versus amsacrine in acute myelogenous leukemia in relapse: a Leukemia Intergroup Study. ( Brennan, J; Browman, G; Goldberg, J; Gottlieb, AJ; Grunwald, H; Miller, KB; Preisler, HD; Rai, K; Vogler, WR; Winton, EF, 1986) |
| "Bortezomib, a proteasome inhibitor, has been used for patients with refractory and relapsed multiple myeloma, lymphoma and leukemia." | 3.74 | The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients. ( Jin, J; Li, Y; Meng, H; Qian, J; Tong, Y, 2007) |
| "The topoisomerase (topo) II-directed agents etoposide, daunorubicin (DNR), and amsacrine (m-AMSA) are widely used in the treatment of acute myelogenous leukemia (AML)." | 3.69 | Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia. ( Burke, PJ; Cowan, K; Jones, RJ; Karp, JE; Kaufmann, SH; Miller, CB; Schneider, E; Wendel, K; Zwelling, LA, 1994) |
| "The role of amsacrine in inducing remission in patients with cardiac disease and acute leukemia was evaluated." | 3.68 | Amsacrine is safe and effective therapy for patients with myocardial dysfunction and acute leukemia. ( Ahmed, T; Arlin, ZA; Baskind, P; Chun, HG; Cook, P; Feldman, EJ; Marboe, C; Mehta, R; Mittelman, A; Puccio, C, 1991) |
| " The overall complete remission rate was 27/78 (35%) in acute myelogenous leukemia and 5/9 (56%) in acute lymphocytic leukemia or acute undifferentiated leukemia for cytosine arabinoside combined with either anthracyclines (rubidazone or Adriamycin [doxorubicin]) or m-AMSA (amsacrine)." | 3.67 | Intensive treatment of acute leukemia in adults 70 years of age and older. ( Estey, EH; Freireich, EJ; Kantarjian, HM; Keating, MJ; McCredie, KB; Walters, RS, 1987) |
| "We describe 2 patients in whom a sustained remission of longstanding rheumatoid arthritis occurred with treatment for acute myelogenous leukemia (cytosine arabinoside, daunorubicin, and m-AMSA), even though both illnesses had been refractory to therapy with standard disease-modifying agents." | 3.67 | Remission of rheumatoid arthritis with the successful treatment of acute myelogenous leukemia with cytosine arabinoside, daunorubicin, and m-AMSA. ( Jones, RJ; Karp, JE; Roubenoff, R; Stevens, MB, 1987) |
| "Twenty-six adults with refractory leukemia were treated with amsacrine gluconate, a new formulation." | 3.66 | Phase II study of amsacrine gluconate in refractory leukemia. ( Grillo-Lopez, AJ; Omura, GA; Vogler, WR; Winton, EF; Zuckerman, KS, 1983) |
| "Strategies to reduce recurrence are urgently required." | 3.01 | Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia. ( Andrew, G; Byrne, J; Craddock, C; Crawley, C; Dillon, R; Freeman, SD; Gilleece, M; Hodgkinson, A; Hunter, A; Jackson, A; Khan, N; Loke, J; Malladi, R; Mason, J; McCarthy, N; Nagra, S; Parker, A; Pavlu, J; Peniket, A; Potter, V; Protheroe, R; Salim, R; Siddique, S; Tholouli, E; Vyas, P; Wheatley, K; Wilson, K, 2021) |
| "Patients with acute myeloid leukemia (AML) in first relapse after initial Complete Remission (CR) lasting ≥1 month were stratified per the European Prognostic Index (EPI) into favorable, intermediate, and poor-risk groups based on duration of first CR, cytogenetics, age, and transplant history." | 2.80 | Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML. ( Cortes, JE; Feldman, EJ; Goldberg, SL; Hogge, DE; Kantarjian, H; Kolitz, JE; Larson, M; Louie, AC; Pigneux, A; Recher, C; Rizzeri, DA; Schiller, G; Warzocha, K, 2015) |
| "We treated 305 de novo acute myeloid leukemia (AML) patients aged | 2.71 | Risk-adapted induction and consolidation therapy in adults with de novo AML aged Arnold, R; Bergmann, L; Fiedler, W; Ganser, A; Heil, G; Hoelzer, D; Kirchner, H; Krauter, J; Lübbert, M; Noens, L; Raghavachar, A; Schlimok, G, 2004) |
| "Twenty-nine patients with acute myeloid leukemia (AML) received a salvage therapy of amsacrine plus IDAC and etoposide, while 22 patients with acute lymphoblastic leukemia (ALL) received amsacrine plus IDAC." | 2.71 | Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia. ( Ahn, BM; Baek, JH; Jeon, SB; Kim, DH; Kim, JG; Lee, KB; Moon, JH; Sohn, SK; Sung, WJ, 2005) |
| "5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin has been applied in a treatment protocol for patients with a relapse of acute myeloid or lymphocytic leukemia." | 2.68 | A randomized phase II study on the effects of 5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893). ( Archimbaud, E; Berneman, Z; Dardenne, M; Dohner, H; Jaksic, B; Jehn, U; Labar, B; Louwagie, EA; Muus, P; Stryckmans, P; Suciu, S; Tjean, M; Wijermans, P; Willemze, R; Zittoun, R, 1997) |
| " An additional 17 patients received those two agents plus azacitidine at a dosage of 250 mg/M2 on days 4 and 5." | 2.67 | Toxicity trials of amsacrine (AMSA) and etoposide +/- azacitidine (AZ) in childhood acute non-lymphocytic leukemia (ANLL): a pilot study. ( Camitta, B; Holbrook, T; Krischer, J; Land, VJ; Sexauer, C; Steuber, CP, 1991) |
| " Further investigation of this drug combination in untreated patients with ANLL is warranted." | 2.66 | Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol. ( Andreeff, M; Arlin, ZA; Berman, E; Gaynor, J; Gee, T; Kempin, SJ; Mertelsmann, R; Miller, W; Nahmias, N; Reich, L, 1989) |
| "Since 1980, adults with acute myelocytic leukemia (AML) have been treated on two clinical studies using intensive timed sequential therapy." | 2.66 | A two-step timed sequential treatment for acute myelocytic leukemia. ( Braine, HG; Burke, PJ; Fox, MG; Geller, RB; Hall, KL; Humphrey, RL; Karp, JE; Morrell, L; Tucker, RW; Zahurak, M, 1989) |
| "Amsacrine is an effective replacement for daunorubicin in the treatment of APL, and its use does not compromise the favorable remission duration characteristic of APL." | 2.65 | Primary therapy of acute promyelocytic leukemia: results of amsacrine- and daunorubicin-based therapy. ( Arlin, Z; Chaganti, RS; Clarkson, B; Gee, T; Higgins, C; Jhanwar, S; Kempin, S; Mertelsmann, R, 1984) |
| "This first described case of toxic megacolon following leukaemia treatment is compared with three previously described cases following cytotoxic chemotherapy for other conditions." | 2.39 | Toxic megacolon complicating chemotherapy for acute myeloid leukaemia. ( Reilly, JT; Snowden, JA; Wodziński, MA, 1994) |
| "HDARAC is also active in acute lymphocytic leukemia." | 2.37 | High dose cytarabine: a review. ( Bolwell, BJ; Cassileth, PA; Gale, RP, 1988) |
| "FLAG-amsacrine was an effective bridge to allogeneic transplant with 38% successfully transplanted with excellent outcomes (median OS not reached)." | 1.39 | Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effective salvage therapy option for acute myeloid leukemia at first relapse. ( Avery, S; Campbell, P; Coutsouvelis, J; Fong, CY; Grigoriadis, G; Hocking, J; Muirhead, J; Patil, S; Paul, E; Schwarer, A; Spencer, A; Walker, P; Wei, A, 2013) |
| "This trial determined that it is safe and feasible to include gemtuzumab ozogamicin in combination with intensive chemotherapy." | 1.38 | AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group. ( Alonzo, TA; Arceci, RJ; Cooper, TM; Feusner, J; Franklin, J; Gamis, A; Gerbing, RB; Hirsch, B; Hurwitz, C; Iannone, R; Lavey, RS; Mathew, P; Meshinchi, S; Raimondi, SC; Smith, FO, 2012) |
| "The prognosis for DS acute myeloid leukemia (AML) is better than for non-DS AML, but the clinical outcome of DS acute lymphoblastic leukemia (ALL) is equal to that of non-DS ALL." | 1.31 | Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. ( Creutzig, U; de Vries, E; Hählen, K; Huismans, DR; Janka-Schaub, GE; Jansen, G; Kaspers, GJ; Peters, GJ; Pieters, R; Rots, MG; van Zantwijk, CH; Veerman, AJ; Zwaan, CM, 2002) |
| " The intra-individual variation was much less, suggesting that dose adjustment based on pharmacokinetic data might be useful in the future." | 1.30 | In vitro cytotoxic drug activity and in vivo pharmacokinetics in childhood acute myeloid leukemia. ( Frost, BM; Larsson, R; Liliemark, E; Lönnerholm, G; Nygren, P; Peterson, C, 1999) |
| "Treatment-related acute myeloid leukemia (t-AML) following successful therapy of a primary malignancy has been recognized with increasing frequency among cancer survivors over the past several years." | 1.30 | Topoisomerase II inhibitors induce DNA double-strand breaks at a specific site within the AML1 locus. ( Aplan, PD; Chervinsky, DS; Stanulla, M; Wang, J, 1997) |
| "Ten patients with acute myeloblastic leukemia (AML) in first relapse were treated with high-dose cytosine-arabinoside (ara-C, 3 g/m2/12 hours x 4) and amsacrine (150 mg/m2/day x 5)." | 1.29 | Treatment of relapsed acute myeloid leukemia using GM-CSF before intensive chemotherapy. ( Belloc, F; Bernard, P; Boiron, JM; Cony-Makhoul, P; Dumain, P; Lacombe, F; Laurent, G; Marit, G; Puntous, M; Reiffers, J, 1993) |
| "Samples from 31 patients with acute myelocytic leukemia (AML) were tested with continuous drug exposure." | 1.29 | Interactions between cladribine (2-chlorodeoxyadenosine) and standard antileukemic drugs in primary cultures of human tumor cells from patients with acute myelocytic leukemia. ( Fridborg, H; Killander, A; Kristensen, J; Larsson, R; Liliemark, J; Nygren, P; Oberg, G; Simonsson, B, 1994) |
| "Twenty-one acute myelogenous leukemia (AML) patients were submitted in second remission (II CR) to BAVC conditioning regimen followed by unpurged ABMT." | 1.28 | BAVC regimen and autologous bone marrow transplantation in patients with acute myelogenous leukemia in second remission. ( De Fabritiis, P; Mandelli, F; Meloni, G; Petti, MC, 1990) |
| "Thus, the CR rate for relapsed ANLL patients who received the higher doses of both agents was 40% (13 of 33)." | 1.28 | Effective reinduction therapy for childhood acute nonlymphoid leukemia using simultaneous continuous infusions of teniposide and amsacrine. ( Dahl, GV; Grier, HE; Kalwinsky, DK; Mason, C; Mirro, J; Murphy, SB; Santana, VM, 1989) |
| "A case of necrotizing fasciitis of the vulva arising in a leukemic patient during a chemotherapy nadir is presented." | 1.28 | Necrotizing fasciitis of the vulva during chemotherapy. ( Hoffman, MS; Turnquist, D, 1989) |
| " Dosage was 75 mg/m2, iv, day 1-7, all 3-5 weeks." | 1.27 | [Phase II study of AMSA in adults with acute therapy-refractory leukemias]. ( Engelhardt, R; Fiebig, HH; Henss, H; Hoelzer, D; Link, H; Pralle, H; Schmitz, R, 1983) |
| " Resistance was not due to a decrease in the bioavailability of the drug." | 1.27 | Development and characterization of a human myelogenous leukemia cell line resistant to 4'-(9-acridinylamino)-3-methanesulfon-m-anisidide. ( Andersson, BS; Beran, M, 1987) |
| " The LD50 values observed in normal and leukemic Brown-Norway rats were 26." | 1.27 | AMSA: in vivo log cell kill for leukemic clonogenic cells versus toxicity for normal hemopoietic stem cells in a rat model for human acute myelocytic leukemia (BNML). ( Hagenbeek, A; Martens, AC, 1986) |
| "Five children treated for acute myeloid leukemia according to the BFM protocol AML 83 experienced first bone marrow relapse after 7, 10, 14, 18, and 30 months and were retreated for second remission induction." | 1.27 | Effective remission induction in children with recurrent acute myeloid leukemia by mAMSA, Ara-C, and VP 16. ( Berthold, F; Creutzig, U; Lampert, F, 1987) |
| "27 patients with resistant acute myelogenous leukemia (AML) were treated with AMSA." | 1.27 | AMSA: a phase II trial in resistant and recurrent acute myelogenous leukemia. ( Boccia, R; Champlin, RE; Gale, RP; Kim, CC; Zighelboim, J, 1984) |
| "Amsacrine, 90 mg/m2, was given daily for 5-8 days to 45 patients with acute myeloblastic leukemia, 15 patients with acute lymphoblastic leukemia, and six patients with blastic transformation of chronic granulocytic leukemia." | 1.27 | Amsacrine in refractory adult acute leukemia: a pilot study of the Southeastern Cancer Study Group. ( Hearn, EB; Johnson, L; Logan, T; Raney, M; Vogler, WR; Winton, EF, 1983) |
| "Etoposide was administered on days 1 and 5 with a constant loading dose of 100 mg/m2 by an 1-h infusion followed by a 23-h infusion, the dose of which was escalated in 3 steps from 110 mg/m2 to 200 mg/m2 and 230 mg/m2." | 1.27 | [Combined therapy with AMSA and etoposide (VP 16-213) in refractory acute myeloid leukemia. A phase I study]. ( Achterrath, W; Balleisen, L; Büchner, T; Hiddemann, W; Kirchhof, B; Preusser, P; Stenzinger, W; Urbanitz, D, 1984) |
| "Amsacrine was also found to be highly bound to plasma proteins (96." | 1.27 | Pharmacokinetics of amsacrine in patients receiving combined chemotherapy for treatment of acute myelogenous leukemia. ( Jurlina, JL; Paxton, JW; Varcoe, AR, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 78 (49.06) | 18.7374 |
| 1990's | 56 (35.22) | 18.2507 |
| 2000's | 11 (6.92) | 29.6817 |
| 2010's | 11 (6.92) | 24.3611 |
| 2020's | 3 (1.89) | 2.80 |
| Authors | Studies |
|---|---|
| Meur, GL | 1 |
| Plesa, A | 1 |
| Larcher, MV | 1 |
| Fossard, G | 1 |
| Barraco, F | 1 |
| Loron, S | 1 |
| Balsat, M | 1 |
| Ducastelle-Leprêtre, S | 1 |
| Gilis, L | 1 |
| Thomas, X | 1 |
| Ghesquières, H | 1 |
| Tigaud, I | 1 |
| Hayette, S | 1 |
| Huet, S | 1 |
| Sujobert, P | 1 |
| Renault, M | 1 |
| Thérèse, RM | 1 |
| Michallet, M | 2 |
| Labussière-Wallet, H | 1 |
| Heiblig, M | 1 |
| Kuron, D | 1 |
| Pohlmann, A | 1 |
| Angenendt, L | 1 |
| Kessler, T | 2 |
| Mesters, R | 1 |
| Berdel, WE | 3 |
| Stelljes, M | 1 |
| Lenz, G | 1 |
| Schliemann, C | 2 |
| Mikesch, JH | 1 |
| Craddock, C | 1 |
| Jackson, A | 1 |
| Loke, J | 1 |
| Siddique, S | 1 |
| Hodgkinson, A | 1 |
| Mason, J | 1 |
| Andrew, G | 1 |
| Nagra, S | 1 |
| Malladi, R | 1 |
| Peniket, A | 1 |
| Gilleece, M | 1 |
| Salim, R | 1 |
| Tholouli, E | 1 |
| Potter, V | 1 |
| Crawley, C | 1 |
| Wheatley, K | 1 |
| Protheroe, R | 1 |
| Vyas, P | 1 |
| Hunter, A | 1 |
| Parker, A | 1 |
| Wilson, K | 1 |
| Pavlu, J | 1 |
| Byrne, J | 1 |
| Dillon, R | 1 |
| Khan, N | 1 |
| McCarthy, N | 1 |
| Freeman, SD | 1 |
| Schaich, M | 1 |
| Parmentier, S | 1 |
| Kramer, M | 1 |
| Illmer, T | 1 |
| Stölzel, F | 1 |
| Röllig, C | 1 |
| Thiede, C | 1 |
| Hänel, M | 1 |
| Schäfer-Eckart, K | 1 |
| Aulitzky, W | 1 |
| Einsele, H | 1 |
| Ho, AD | 1 |
| Serve, H | 2 |
| Mayer, J | 2 |
| Schmitz, N | 1 |
| Krause, SW | 1 |
| Neubauer, A | 2 |
| Baldus, CD | 1 |
| Schetelig, J | 1 |
| Bornhäuser, M | 1 |
| Ehninger, G | 1 |
| Krejci, M | 1 |
| Doubek, M | 1 |
| Dusek, J | 1 |
| Brychtova, Y | 1 |
| Racil, Z | 1 |
| Navratil, M | 1 |
| Tomiska, M | 1 |
| Horky, O | 1 |
| Pospisilova, S | 1 |
| Feliu, J | 1 |
| Clay, J | 1 |
| Raj, K | 1 |
| Barber, L | 1 |
| Devlia, V | 1 |
| Shaw, B | 1 |
| Pagliuca, A | 1 |
| Mufti, G | 1 |
| Cortes, JE | 1 |
| Goldberg, SL | 1 |
| Feldman, EJ | 2 |
| Rizzeri, DA | 1 |
| Hogge, DE | 1 |
| Larson, M | 1 |
| Pigneux, A | 1 |
| Recher, C | 1 |
| Schiller, G | 1 |
| Warzocha, K | 1 |
| Kantarjian, H | 2 |
| Louie, AC | 1 |
| Kolitz, JE | 1 |
| Pfrepper, C | 1 |
| Klink, A | 1 |
| Behre, G | 1 |
| Schenk, T | 1 |
| Franke, GN | 1 |
| Jentzsch, M | 1 |
| Schwind, S | 1 |
| Al-Ali, HK | 1 |
| Hochhaus, A | 1 |
| Niederwieser, D | 1 |
| Sayer, HG | 1 |
| Malard, F | 1 |
| Labopin, M | 3 |
| Stuhler, G | 1 |
| Bittenbring, J | 1 |
| Ganser, A | 2 |
| Tischer, J | 3 |
| Kröger, N | 1 |
| Schmid, C | 3 |
| Huynh, A | 1 |
| Hallek, M | 1 |
| Savani, BN | 1 |
| Mohty, M | 1 |
| Nagler, A | 1 |
| Schleuning, M | 2 |
| Holler, E | 1 |
| Haude, KH | 1 |
| Braess, J | 1 |
| Haferlach, C | 1 |
| Baurmann, H | 1 |
| Oruzio, D | 1 |
| Hahn, J | 1 |
| Spiekermann, K | 1 |
| Schlimok, G | 2 |
| Schwerdtfeger, R | 1 |
| Buechner, T | 1 |
| Hiddemann, W | 3 |
| Kolb, HJ | 2 |
| Wilhelm, C | 1 |
| Burchert, A | 1 |
| Cooper, TM | 1 |
| Franklin, J | 1 |
| Gerbing, RB | 1 |
| Alonzo, TA | 1 |
| Hurwitz, C | 1 |
| Raimondi, SC | 1 |
| Hirsch, B | 1 |
| Smith, FO | 1 |
| Mathew, P | 1 |
| Arceci, RJ | 1 |
| Feusner, J | 1 |
| Iannone, R | 1 |
| Lavey, RS | 1 |
| Meshinchi, S | 1 |
| Gamis, A | 1 |
| Saure, C | 1 |
| Schroeder, T | 1 |
| Zohren, F | 1 |
| Groten, A | 1 |
| Bruns, I | 1 |
| Czibere, A | 1 |
| Galonska, L | 1 |
| Kondakci, M | 1 |
| Weigelt, C | 1 |
| Fenk, R | 1 |
| Germing, U | 1 |
| Haas, R | 1 |
| Kobbe, G | 1 |
| Fong, CY | 1 |
| Grigoriadis, G | 1 |
| Hocking, J | 1 |
| Coutsouvelis, J | 1 |
| Muirhead, J | 1 |
| Campbell, P | 1 |
| Paul, E | 1 |
| Walker, P | 1 |
| Avery, S | 1 |
| Patil, S | 1 |
| Spencer, A | 1 |
| Schwarer, A | 1 |
| Wei, A | 1 |
| Locatelli, F | 1 |
| Ortega, J | 1 |
| Meloni, G | 8 |
| Dini, G | 1 |
| Messina, C | 1 |
| Yaniv, I | 1 |
| Fagioli, F | 1 |
| Castel, V | 1 |
| Shaw, PJ | 1 |
| Ferrant, A | 2 |
| Pession, A | 1 |
| Sociè, G | 1 |
| Frassoni, F | 2 |
| Fouillard, L | 1 |
| Polge, E | 1 |
| Gorin, NC | 1 |
| Heil, G | 1 |
| Krauter, J | 1 |
| Raghavachar, A | 1 |
| Bergmann, L | 1 |
| Hoelzer, D | 2 |
| Fiedler, W | 1 |
| Lübbert, M | 1 |
| Noens, L | 1 |
| Arnold, R | 1 |
| Kirchner, H | 1 |
| Ledderose, G | 1 |
| Boutonnat, J | 1 |
| Faussat, AM | 1 |
| Marie, JP | 6 |
| Bignon, J | 1 |
| Wdzieczak-Bakala, J | 1 |
| Barbier, M | 1 |
| Thierry, J | 1 |
| Ronot, X | 1 |
| Colle, PE | 1 |
| Sung, WJ | 1 |
| Kim, DH | 1 |
| Sohn, SK | 1 |
| Kim, JG | 1 |
| Baek, JH | 1 |
| Jeon, SB | 1 |
| Moon, JH | 1 |
| Ahn, BM | 1 |
| Lee, KB | 1 |
| Tong, Y | 1 |
| Qian, J | 1 |
| Li, Y | 1 |
| Meng, H | 1 |
| Jin, J | 1 |
| Mohr, M | 1 |
| Müller-Tidow, C | 1 |
| Krug, U | 1 |
| Brunnberg, U | 1 |
| Mohr, B | 1 |
| Sauerland, C | 1 |
| Büchner, T | 3 |
| Mesters, RM | 1 |
| Weidenaar, AC | 1 |
| de Jonge, HJ | 1 |
| Fidler, V | 1 |
| ter Elst, A | 1 |
| Meeuwsen-de Boer, T | 1 |
| Douwes, J | 1 |
| Bouma-ter Steege, JC | 1 |
| Hählen, K | 2 |
| Kamps, WA | 1 |
| de Bont, ES | 1 |
| Cabanillas, F | 1 |
| Obrecht, JP | 1 |
| Fiebig, HH | 1 |
| Henss, H | 1 |
| Engelhardt, R | 1 |
| Pralle, H | 1 |
| Link, H | 1 |
| Schmitz, R | 1 |
| Achterrath, W | 2 |
| Urbanitz, D | 2 |
| Preusser, P | 2 |
| Balleisen, L | 2 |
| Kirchhof, B | 1 |
| Stenzinger, W | 1 |
| Hittelman, WN | 1 |
| Menegaz, SD | 1 |
| McCredie, KB | 10 |
| Keating, MJ | 11 |
| Nagura, E | 1 |
| Kawashima, K | 1 |
| Suzuki, H | 1 |
| Ohno, R | 1 |
| Yamada, K | 1 |
| Yokomaku, S | 1 |
| Ogawa, M | 2 |
| Winton, EF | 4 |
| Hearn, EB | 1 |
| Vogler, WR | 4 |
| Johnson, L | 1 |
| Logan, T | 1 |
| Raney, M | 1 |
| Arlin, Z | 1 |
| Kempin, S | 1 |
| Mertelsmann, R | 2 |
| Gee, T | 2 |
| Higgins, C | 1 |
| Jhanwar, S | 1 |
| Chaganti, RS | 1 |
| Clarkson, B | 1 |
| Omura, GA | 2 |
| Zuckerman, KS | 1 |
| Grillo-Lopez, AJ | 1 |
| Estey, EH | 7 |
| Smith, TL | 2 |
| Legha, SS | 3 |
| Walters, RS | 3 |
| Bodey, GP | 3 |
| Freireich, EJ | 12 |
| Boccia, R | 1 |
| Zighelboim, J | 1 |
| Champlin, RE | 2 |
| Kim, CC | 1 |
| Gale, RP | 3 |
| Case, DC | 1 |
| Epstein, J | 1 |
| Preisler, HD | 2 |
| Weil, M | 1 |
| Auclerc, MF | 1 |
| Schaison, G | 3 |
| Auclerc, G | 1 |
| Daubrisson, A | 1 |
| Degos, L | 1 |
| Caro, J | 1 |
| Marty, M | 2 |
| Jacquillat, GI | 1 |
| Zander, AR | 2 |
| Issell, BF | 1 |
| Buick, RN | 1 |
| Chang, LJ | 1 |
| Messner, HA | 1 |
| Curtis, JE | 1 |
| McCulloch, EA | 1 |
| Slevin, ML | 1 |
| Shannon, MS | 2 |
| Prentice, HG | 3 |
| Goldman, AJ | 1 |
| Lister, TA | 3 |
| Goldman, A | 1 |
| Malpas, JS | 2 |
| Lawrence, HJ | 1 |
| Ries, CA | 1 |
| Reynolds, RD | 1 |
| Lewis, JP | 1 |
| Koretz, MM | 1 |
| Torti, FM | 1 |
| Dupont, JC | 1 |
| Garay, GE | 1 |
| Scaghone, C | 1 |
| Pavlovsky, S | 1 |
| Woodley, PV | 1 |
| Volger, WR | 1 |
| Weiner, RS | 1 |
| Moore, JO | 1 |
| Bartolucci, AA | 1 |
| Stagg, M | 1 |
| Zittoun, RA | 1 |
| Mandelli, F | 8 |
| Willemze, R | 10 |
| de Witte, T | 3 |
| Labar, B | 2 |
| Resegotti, L | 1 |
| Leoni, F | 1 |
| Damasio, E | 1 |
| Visani, G | 1 |
| Papa, G | 1 |
| Wodziński, MA | 1 |
| Snowden, JA | 1 |
| Reilly, JT | 1 |
| Kaufmann, SH | 1 |
| Karp, JE | 3 |
| Jones, RJ | 2 |
| Miller, CB | 1 |
| Schneider, E | 1 |
| Zwelling, LA | 4 |
| Cowan, K | 1 |
| Wendel, K | 1 |
| Burke, PJ | 2 |
| Kristensen, J | 1 |
| Nygren, P | 2 |
| Liliemark, J | 1 |
| Fridborg, H | 1 |
| Killander, A | 2 |
| Simonsson, B | 1 |
| Oberg, G | 1 |
| Larsson, R | 2 |
| Ghaddar, HM | 1 |
| Plunkett, W | 3 |
| Kantarjian, HM | 4 |
| Pierce, S | 1 |
| Puntous, M | 1 |
| Lacombe, F | 1 |
| Dumain, P | 1 |
| Marit, G | 3 |
| Cony-Makhoul, P | 1 |
| Belloc, F | 1 |
| Boiron, JM | 2 |
| Laurent, G | 1 |
| Bernard, P | 2 |
| Reiffers, J | 3 |
| Daenen, S | 1 |
| Löwenberg, B | 5 |
| Sonneveld, P | 1 |
| van Putten, WL | 1 |
| Verhoef, G | 1 |
| Verdonck, LF | 2 |
| van Veldhoven, M | 1 |
| Huijgens, PC | 2 |
| Delmer, A | 2 |
| Thevenin, D | 2 |
| Suberville, AM | 3 |
| Zittoun, R | 12 |
| Jehn, U | 10 |
| Heinemann, V | 2 |
| Rio, B | 2 |
| Vekhof, A | 1 |
| Tura, S | 1 |
| Ferrini, PR | 1 |
| Stryckmans, P | 4 |
| Steuber, CP | 2 |
| Krischer, J | 2 |
| Holbrook, T | 2 |
| Camitta, B | 2 |
| Land, V | 1 |
| Sexauer, C | 2 |
| Mahoney, D | 1 |
| Weinstein, H | 1 |
| Hardegger, TP | 1 |
| von Rohr, A | 1 |
| Tobler, A | 1 |
| Fey, MF | 1 |
| Vignetti, M | 2 |
| Avvisati, G | 1 |
| Capria, S | 1 |
| Micozzi, A | 1 |
| Giona, F | 1 |
| Stanulla, M | 1 |
| Wang, J | 1 |
| Chervinsky, DS | 1 |
| Aplan, PD | 1 |
| Suciu, S | 3 |
| Archimbaud, E | 1 |
| Muus, P | 2 |
| Louwagie, EA | 1 |
| Berneman, Z | 1 |
| Tjean, M | 1 |
| Wijermans, P | 1 |
| Dohner, H | 1 |
| Jaksic, B | 1 |
| Dardenne, M | 1 |
| Sundström, GM | 1 |
| Wahlin, A | 2 |
| Elonen, E | 1 |
| Almqvist, A | 1 |
| Hänninen, A | 1 |
| Jansson, SE | 1 |
| Järventie, G | 1 |
| Koistinen, P | 1 |
| Koivunen, E | 1 |
| Lahtinen, R | 1 |
| Lehtinen, M | 1 |
| Nousiainen, T | 1 |
| Pelliniemi, TT | 1 |
| Rajamäki, A | 1 |
| Remes, K | 1 |
| Timonen, T | 1 |
| Vilpo, J | 1 |
| Volin, L | 1 |
| Ruutu, T | 1 |
| Beksaç, M | 1 |
| Arslan, O | 1 |
| Koç, H | 1 |
| Akan, H | 1 |
| Ilhan, O | 1 |
| Arat, M | 1 |
| Ozcan, M | 1 |
| Gürman, G | 1 |
| Konuk, N | 1 |
| Uysal, A | 1 |
| Möllgård, L | 1 |
| Tidefelt, U | 2 |
| Sundman-Engberg, B | 1 |
| Löfgren, C | 1 |
| Lehman, S | 1 |
| Paul, C | 2 |
| Lönnerholm, G | 1 |
| Frost, BM | 1 |
| Liliemark, E | 1 |
| Peterson, C | 1 |
| Zwaan, CM | 1 |
| Kaspers, GJ | 1 |
| Pieters, R | 1 |
| Janka-Schaub, GE | 1 |
| van Zantwijk, CH | 1 |
| Huismans, DR | 1 |
| de Vries, E | 1 |
| Rots, MG | 1 |
| Peters, GJ | 1 |
| Jansen, G | 1 |
| Creutzig, U | 2 |
| Veerman, AJ | 1 |
| Perel, Y | 1 |
| Auvrignon, A | 1 |
| Leblanc, T | 1 |
| Vannier, JP | 1 |
| Michel, G | 1 |
| Nelken, B | 1 |
| Gandemer, V | 1 |
| Schmitt, C | 1 |
| Lamagnere, JP | 1 |
| De Lumley, L | 1 |
| Bader-Meunier, B | 1 |
| Couillaud, G | 1 |
| Landman-Parker, J | 1 |
| Thuret, I | 1 |
| Dalle, JH | 1 |
| Baruchel, A | 1 |
| Leverger, G | 2 |
| Maschmeyer, G | 1 |
| Willborn, K | 1 |
| Heit, W | 1 |
| Legrand, O | 1 |
| Russo, D | 1 |
| Zhou, D | 1 |
| Hurwitz, CA | 1 |
| Krance, R | 1 |
| Schell, MJ | 1 |
| Santana, VM | 2 |
| Brenner, MK | 1 |
| Ribeirio, R | 1 |
| Roberts, WM | 1 |
| Mahmoud, H | 1 |
| Belt, J | 1 |
| Crom, W | 1 |
| Evensen, SA | 1 |
| Brinch, L | 1 |
| Stavem, P | 1 |
| Tjønnfjord, G | 1 |
| Hansz, J | 1 |
| Bajko, G | 1 |
| Woźny, T | 1 |
| Drozdowska, D | 1 |
| Berman, E | 2 |
| Estey, E | 2 |
| O'Brien, S | 1 |
| Koller, C | 1 |
| Beran, M | 5 |
| Gahrton, G | 1 |
| Björkholm, M | 1 |
| Grimfors, G | 1 |
| Hast, R | 1 |
| Juliusson, G | 1 |
| Järnmark, M | 1 |
| Kimby, E | 1 |
| Spinolo, JA | 1 |
| Dicke, KA | 1 |
| Horwitz, LJ | 1 |
| Jagannath, S | 1 |
| Auber, ML | 1 |
| Spitzer, G | 1 |
| Rees, JK | 3 |
| Gray, RG | 1 |
| Fiere, D | 2 |
| Haanen, C | 4 |
| Peetermans, M | 2 |
| Solbu, G | 2 |
| Miller, LP | 1 |
| Pyesmany, AF | 1 |
| Wolff, LJ | 1 |
| Rogers, PC | 1 |
| Siegel, SE | 1 |
| Wells, RJ | 1 |
| Buckley, JD | 1 |
| Hammond, GD | 1 |
| Land, VJ | 1 |
| Ortega Aramburu, JJ | 1 |
| Olivé Oliveras, T | 1 |
| Javier Manchón, G | 1 |
| Bastida Vila, P | 1 |
| Sánchez, C | 1 |
| Giralt López, J | 1 |
| Arlin, ZA | 5 |
| Mittelman, A | 2 |
| Ahmed, T | 2 |
| Puccio, C | 1 |
| Chun, HG | 1 |
| Cook, P | 1 |
| Baskind, P | 2 |
| Marboe, C | 1 |
| Mehta, R | 2 |
| De Fabritiis, P | 4 |
| Petti, MC | 4 |
| Pinto, MR | 1 |
| Testi, AM | 1 |
| Vegna, ML | 1 |
| Bach, F | 1 |
| Videbaek, C | 1 |
| Holst-Christensen, J | 1 |
| Boesby, S | 1 |
| Limonta, M | 1 |
| Ubezio, P | 1 |
| Catapano, CV | 1 |
| Conter, V | 1 |
| Costato, C | 1 |
| Masera, G | 1 |
| Specchia, G | 1 |
| Liso, V | 1 |
| Barbui, T | 1 |
| Giudici, G | 1 |
| Petros, WP | 1 |
| Rodman, JH | 1 |
| Mirro, J | 2 |
| Evans, WE | 1 |
| Hansen, OP | 1 |
| Pedersen-Bjergaard, J | 1 |
| Ellegaard, J | 1 |
| Brincker, H | 1 |
| Boesen, AM | 1 |
| Christensen, BE | 1 |
| Drivsholm, A | 1 |
| Hippe, E | 1 |
| Jans, H | 1 |
| Jensen, KB | 1 |
| Cassileth, PA | 3 |
| Harrington, DP | 1 |
| Hines, JD | 1 |
| Oken, MM | 1 |
| Mazza, JJ | 1 |
| McGlave, P | 1 |
| Bennett, JM | 1 |
| Lynch, E | 1 |
| O'Connell, MJ | 1 |
| Martiat, P | 1 |
| Ghilain, JM | 1 |
| Doyen, C | 1 |
| Delannoy, A | 1 |
| Chatelain, C | 1 |
| Bosly, A | 1 |
| Michaux, JL | 1 |
| Sokal, G | 1 |
| Stein, RS | 1 |
| Cohen, HJ | 1 |
| Raney, MR | 1 |
| Bartolucci, A | 1 |
| Skinner, WL | 1 |
| Murray, D | 1 |
| Kohli, V | 1 |
| Andersson, BS | 4 |
| Harousseau, JL | 2 |
| Milpied, N | 1 |
| Briere, J | 1 |
| Desablens, B | 2 |
| Le Prise, PY | 1 |
| Ifrah, N | 1 |
| Gandhour, C | 1 |
| Casassus, P | 1 |
| Davis, CL | 1 |
| Rohatiner, AZ | 1 |
| Amess, J | 1 |
| Lim, J | 1 |
| Estienne, MH | 1 |
| Fenaux, P | 1 |
| Preudhomme, C | 1 |
| Lai, JL | 1 |
| Zandecki, M | 1 |
| Lepelley, P | 1 |
| Cosson, A | 1 |
| Dekker, AW | 1 |
| Nieuwenhuis, HK | 1 |
| De Pauw, B | 1 |
| Marcus, RE | 1 |
| Catovsky, D | 1 |
| Newland, AC | 1 |
| Chessells, JM | 1 |
| Stevens, RF | 1 |
| Hann, IM | 1 |
| Goldman, JM | 1 |
| Hoffbrand, AV | 1 |
| Galton, DA | 1 |
| Gray, R | 2 |
| Hayhoe, FG | 1 |
| Rice, A | 1 |
| Vezon, G | 1 |
| Abels, J | 1 |
| Bury, J | 2 |
| Hayat, M | 1 |
| Amadori, S | 1 |
| Pulsoni, A | 2 |
| Sandrelli, A | 2 |
| Linkesch, W | 1 |
| Michlmayr, G | 1 |
| Gerhartz, H | 1 |
| Illinger, H | 1 |
| König, H | 1 |
| Düllmann, J | 1 |
| Keilhauer, R | 1 |
| Moldrzyk, D | 1 |
| Geller, RB | 1 |
| Humphrey, RL | 1 |
| Braine, HG | 1 |
| Tucker, RW | 1 |
| Fox, MG | 1 |
| Zahurak, M | 1 |
| Morrell, L | 1 |
| Hall, KL | 1 |
| Mukaiyama, T | 1 |
| Horikoshi, N | 1 |
| Inoue, K | 1 |
| Fukutani, H | 1 |
| Tabata, M | 1 |
| Hirano, A | 1 |
| Mizunuma, N | 1 |
| Itami, S | 1 |
| Kalwinsky, DK | 1 |
| Grier, HE | 1 |
| Mason, C | 1 |
| Murphy, SB | 1 |
| Dahl, GV | 1 |
| Hoffman, MS | 1 |
| Turnquist, D | 1 |
| Bakic, M | 2 |
| Chan, D | 1 |
| Marton, LJ | 1 |
| Gaynor, J | 1 |
| Miller, W | 1 |
| Kempin, SJ | 1 |
| Andreeff, M | 1 |
| Reich, L | 1 |
| Nahmias, N | 1 |
| Sahyoun, N | 1 |
| Wolf, M | 1 |
| Besterman, J | 1 |
| Hsieh, T | 1 |
| Sander, M | 1 |
| LeVine, H | 1 |
| Chang, KJ | 1 |
| Cuatrecasas, P | 1 |
| Silberman, LE | 1 |
| Newman, RA | 1 |
| Silberman, L | 1 |
| Jager, U | 1 |
| Burghouts, J | 1 |
| Walters, R | 1 |
| Smith, T | 1 |
| Blanc, CM | 1 |
| Peters, WG | 4 |
| Colly, LP | 2 |
| Carter, C | 1 |
| Winfield, DA | 1 |
| Knüppel, W | 1 |
| Wilmanns, W | 1 |
| Bolwell, BJ | 1 |
| Lepage, E | 1 |
| Guy, H | 1 |
| Bordessoule, D | 1 |
| Guilhot, F | 1 |
| Boiron, M | 1 |
| Covelli, A | 1 |
| Simone, F | 1 |
| Tschopp, L | 1 |
| von Fliedner, VE | 1 |
| Sauter, C | 1 |
| Maurice, P | 1 |
| Gratwohl, A | 1 |
| Fopp, M | 1 |
| Cavalli, F | 1 |
| Dalton, WT | 1 |
| Cork, A | 1 |
| Trujillo, JM | 1 |
| Brox, LW | 1 |
| Belch, A | 1 |
| Ng, A | 1 |
| Pollock, E | 1 |
| Dhaliwal, HS | 1 |
| Barnett, MJ | 1 |
| Bragman, K | 1 |
| Hagenbeek, A | 1 |
| Martens, AC | 1 |
| Child, JA | 1 |
| Norfolk, DR | 1 |
| Franks, CR | 1 |
| Nys, G | 1 |
| Ossenkoppele, GJ | 1 |
| van der Weide, M | 1 |
| Wijngaarden, MJ | 1 |
| Reijneke, RM | 1 |
| Wijermans, PW | 1 |
| Langenhuijsen, MM | 1 |
| Delanian, S | 1 |
| Decker, RW | 1 |
| Ho, WG | 1 |
| Berthold, F | 1 |
| Lampert, F | 1 |
| Roubenoff, R | 1 |
| Stevens, MB | 1 |
| Tham, RT | 1 |
| de Bruïne, FT | 1 |
| Gottlieb, AJ | 1 |
| Goldberg, J | 1 |
| Brennan, J | 1 |
| Grunwald, H | 1 |
| Rai, K | 1 |
| Browman, G | 1 |
| Miller, KB | 1 |
| Feldman, E | 1 |
| Weinstein, P | 1 |
| Rieber, E | 1 |
| Sullivan, P | 1 |
| Jurlina, JL | 1 |
| Varcoe, AR | 1 |
| Paxton, JW | 1 |
| van Hennik, MB | 1 |
| Fibbe, WE | 1 |
| Kootte, AM | 1 |
| van Berkel, M | 1 |
| Lie, R | 1 |
| Rodenburg, CJ | 1 |
| Veltkamp, JJ | 1 |
| Kucuk, O | 1 |
| Apostol, JV | 1 |
| David, B | 1 |
| Broustet, A | 1 |
| Zittoun, J | 1 |
| Marquet, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Reduced Intensity Conditioning With Fludarabine and Busulfan Versus Fludarabine and Melphalan Before Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Randomised, Single-Center, Phase III Study[NCT05674539] | Phase 3 | 200 participants (Anticipated) | Interventional | 2022-12-28 | Recruiting | ||
| AML2003 - Randomized Comparison Between Standard-Therapy and Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years. A Prospective, Randomized, Multi-center Therapy-Optimizing-Study.[NCT00180102] | Phase 4 | 600 participants (Anticipated) | Interventional | 2003-12-31 | Completed | ||
| Eradicating Measurable Residual Disease in Patients With Acute Myeloid Leukemia (AML) Prior to StEm Cell Transplantation (ERASE): A MyeloMATCH Treatment Trial[NCT05628623] | Phase 2 | 184 participants (Anticipated) | Interventional | 2023-10-23 | Not yet recruiting | ||
| Treatment of Newly Diagnosed Childhood Acute Myeloid Leukemia (AML) Using Intensive MRC-Based Therapy and Gemtuzumab Ozogamicin (GMTZ): A COG Pilot Study[NCT00070174] | Phase 2 | 350 participants (Actual) | Interventional | 2003-12-31 | Completed | ||
| Early Tapering of Immunosuppressive Agents After Allogeneic Hematopoietic Stem Cell Transplantation Can Improve the Survival of Patients With Advanced Acute Myeloid Leukemia.[NCT03150134] | Phase 4 | 100 participants (Anticipated) | Interventional | 2010-01-01 | Recruiting | ||
| DaunoXome (Liposomal Daunorubicin) Plus Ara-C Versus Daunorubicin Plus Ara-C in Elderly AML Patients.A Randomized Phase III Study.[NCT00589082] | Phase 3 | 0 participants | Interventional | 2001-10-31 | Completed | ||
| Feasibility Study of the Use of Intermediate Doses of Cytarabine Associated With Autologous Hematopoietic Stem Cells as Consolidation Treatment of Young Adults With Low- or Intermediate-risk de Novo Acute Myeloid Leukemia[NCT03023384] | 547 participants (Anticipated) | Observational [Patient Registry] | 2016-12-31 | Recruiting | |||
| Prophylactic Infusion of Donor Lymphocytes in Cord Blood Transplantation[NCT02328885] | Phase 1/Phase 2 | 17 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| Multicenter Protocol in Treating Patients With Childhood Acute Myeloid Leukemia. Randomized Study of Maintenance Treatment With Interleukin-2[NCT00149162] | Phase 3 | 580 participants (Anticipated) | Interventional | 2005-03-31 | Recruiting | ||
| A Multi-Center Phase 2 Study of Daratumumab With Pomalidomide and Dexamethasone in Combination With All-Transretinoic Acid in Patients With Multiple Myeloma Previously Exposed to Daratumumab-Based Regimens[NCT04700176] | Phase 2 | 43 participants (Anticipated) | Interventional | 2022-05-02 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for amsacrine and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Toxic megacolon complicating chemotherapy for acute myeloid leukaemia.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposid | 1994 |
New drugs in acute myelogenous leukemia: a review.
Topics: Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as | 1992 |
Evolution of treatment for acute myelogenous leukemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985-1991.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administra | 1992 |
Mitoxantrone and amsacrine: two important agents for the treatment of acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL).
Topics: Amsacrine; Daunorubicin; Drug Evaluation; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Precursor | 1989 |
High dose cytarabine: a review.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cytarabine; Daunorubicin; H | 1988 |
Amsacrine: a review.
Topics: Amsacrine; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemical | 1986 |
59 trials available for amsacrine and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia.
Topics: Adult; Aged; Amsacrine; Busulfan; Cytarabine; Female; Graft vs Host Disease; Humans; Immunosuppressi | 2021 |
High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Ther | 2013 |
Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.
Topics: Adult; Aged; Aminoglycosides; Amsacrine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2015 |
Early allo-SCT for AML with a complex aberrant karyotype--results from a prospective pilot study.
Topics: Abnormal Karyotype; Acute Disease; Adolescent; Adult; Amsacrine; Antilymphocyte Serum; Antineoplasti | 2012 |
Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.
Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; | 2012 |
Risk-adapted induction and consolidation therapy in adults with de novo AML aged
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Ther | 2004 |
Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Diar | 2005 |
Amsacrine containing induction therapy in elderly AML patients: comparison to standard induction regimens in a matched-pair analysis.
Topics: Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Admi | 2008 |
[Current status of the treatment of recurrent acute myeloblastic leukaemia in adults (author's transl)].
Topics: Aminoacridines; Amsacrine; Antineoplastic Agents; Azacitidine; Clinical Trials as Topic; Daunorubici | 1981 |
Premature chromosome condensation studies in human leukemia: 5. Prediction of early relapse.
Topics: Aminoacridines; Amsacrine; Animals; Cell Fusion; Chromosomes; Clinical Trials as Topic; Cricetinae; | 1984 |
Primary therapy of acute promyelocytic leukemia: results of amsacrine- and daunorubicin-based therapy.
Topics: Adult; Aged; Aminoacridines; Amsacrine; Antibiotics, Antineoplastic; Antineoplastic Combined Chemoth | 1984 |
[Clinical activity of m-Amsa and the combination of m-Amsa with cytosine arabinoside].
Topics: Adolescent; Adult; Aminoacridines; Amsacrine; Antineoplastic Agents; Child; Clinical Trials as Topic | 1982 |
AMSA--a promising new agent in refractory acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Child; Cli | 1982 |
Trial of AMSA in acute leukemia.
Topics: Adolescent; Adult; Aminoacridines; Amsacrine; Antineoplastic Agents; Child; Clinical Trials as Topic | 1982 |
Long-term follow-up of a randomized post-induction therapy trial in acute myelogenous leukemia (a Southeastern Cancer Study Group trial).
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabin | 1995 |
Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplant | 1995 |
Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplant | 1995 |
Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplant | 1995 |
Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplant | 1995 |
Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplant | 1995 |
Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplant | 1995 |
Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplant | 1995 |
Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplant | 1995 |
Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplant | 1995 |
Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemotherapy Protocol | 1994 |
Efficacy of etoposide and mitoxantrone in patients with acute myelogenous leukemia refractory to standard induction therapy and intermediate-dose cytarabine with amsidine. Dutch Hematology-Oncology Working Group for Adults (HOVON).
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Respo | 1994 |
[Phase II clinical trial of domestic amsacrine in patients with acute leukemias. Cooperative Group for Treating Acute Leukemias with Domestic m-AMSA].
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relation | 1993 |
Phase-II study of treatment of refractory acute leukemia with intermediate-dose cytosine arabinoside and amsacrine.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug | 1993 |
[Comparison between intensive consolidation by bone marrow autograft or by chemotherapy of acute myeloblastic leukemias in 1st complete remission: AML8A protocol of the Leukemia Cooperative Group of the European Organization for Research and Treatment of
Topics: Actuarial Analysis; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplan | 1993 |
Therapy of refractory or recurrent childhood acute myeloid leukemia using amsacrine and etoposide with or without azacitidine: a Pediatric Oncology Group randomized phase II study.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Ch | 1996 |
BAVC regimen and autograft for acute myelogenous leukemia in second complete remission.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplant | 1996 |
A randomized phase II study on the effects of 5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893).
Topics: Adolescent; Adult; Aged; Amsacrine; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemoth | 1997 |
Comparison of efficacies of ondansetron and dixyrazine for prophylaxis of emesis during induction treatment in acute myelogenous leukemia. A pilot study.
Topics: Adult; Aged; Aged, 80 and over; Amsacrine; Antiemetics; Antineoplastic Combined Chemotherapy Protoco | 1997 |
Comparison between four and eight cycles of intensive chemotherapy in adult acute myeloid leukemia: a randomized trial of the Finnish Leukemia Group.
Topics: Aclarubicin; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cyt | 1998 |
Randomised unicenter trial for comparison of three regimens in de novo adult acute nonlymphoblastic leukaemia.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daun | 1998 |
High single dose of mitoxantrone and cytarabine in acute non-lymphocytic leukemia: a pharmacokinetic and clinical study.
Topics: Adult; Aged; Amsacrine; Chromatography, High Pressure Liquid; Cytarabine; Drug Administration Schedu | 1998 |
Impact of addition of maintenance therapy to intensive induction and consolidation chemotherapy for childhood acute myeloblastic leukemia: results of a prospective randomized trial, LAME 89/91. Leucámie Aiqüe Myéloïde Enfant.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation | 2002 |
AMSA combination chemotherapy in patients with acute myelogenous leukemia unsuitable for standard antileukemic treatment.
Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Heart Di | 1992 |
Current strategies for treatment of acute myeloid leukemia at St Jude Children's Research Hospital.
Topics: 2-Chloroadenosine; Acute Disease; Adolescent; Adult; Amsacrine; Antineoplastic Agents; Antineoplasti | 1992 |
[Effects of alternating as well as long-term intensive polychemotherapy in the remission-maintaining treatment of patients with acute myelocytic leukemia].
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Doxo | 1992 |
DNA as a carrier for anthracyclines in the treatment of acute myelocytic leukemia (AML).
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubic | 1992 |
Remission induction and postremission therapy in acute myelogenous leukemia: British MRC Study.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bon | 1990 |
A randomized comparison of intensive maintenance treatment for adult acute myelogenous leukemia using either cyclic alternating drugs or repeated courses of the induction-type chemotherapy: AML-6 trial of the EORTC Leukemia Cooperative Group.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bel | 1990 |
Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogeneous leukemia.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bon | 1990 |
Successful reinduction therapy with amsacrine and cyclocytidine in acute nonlymphoblastic leukemia in children. A report from the Childrens Cancer Study Group.
Topics: Adolescent; Amsacrine; Ancitabine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chil | 1991 |
Toxicity trials of amsacrine (AMSA) and etoposide +/- azacitidine (AZ) in childhood acute non-lymphocytic leukemia (ANLL): a pilot study.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Ch | 1991 |
[Autotransplantation in acute nonlymphoid leukemia].
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transpla | 1991 |
BAVC regimen in CR AML patients.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplant | 1991 |
Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
Topics: Aclarubicin; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Chi | 1991 |
Comparison of postremission therapies in adult acute myeloid leukemia: preliminary analysis of an ECOG study. Eastern Cooperative Oncology Group.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Tran | 1990 |
High-dose cytosine arabinoside and amsacrine or mitoxantrone in relapsed and refractory acute myeloid leukaemia: a prospective randomized study.
Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; | 1990 |
Therapy of acute myelogenous leukemia in patients over the age of 50: a randomized Southeastern Cancer Study Group trial.
Topics: Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daun | 1990 |
Intensive induction and consolidation chemotherapy for adults and children with acute myeloid leukaemia (AML) joint AML trial 1982-1985.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Clinical Trial | 1987 |
The ninth British Medical Research Council trial for the treatment of acute myeloid leukaemia.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Cy | 1987 |
[AML-6 study of the value of cyclic alternating chemotherapy during remission in acute myelocytic leukemia].
Topics: Adult; Aminoacridines; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc | 1985 |
Alternating v repeated postremission treatment in adult acute myelogenous leukemia: a randomized phase III study (AML6) of the EORTC Leukemia Cooperative Group.
Topics: Adolescent; Adult; Aged; Amsacrine; Child; Clinical Trials as Topic; Cytarabine; Daunorubicin; Human | 1989 |
Amsacrine, cytarabine and thioguanine (AAT) versus daunorubicin, cytarabine, thioguanine (DAT) in adults with untreated acute non-lymphoblastic leukemia (ANLL). Austrian-German results.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemotherapy Protocol | 1989 |
A two-step timed sequential treatment for acute myelocytic leukemia.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials | 1989 |
Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol.
Topics: Age Factors; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Dr | 1989 |
Intensive maintenance treatment in acute myelogenous leukemia (AML): single institution experience of a multicenter randomized trial.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials | 1988 |
Remission induction and maintenance modalities in acute myeloid leukemia: a multicenter randomized study.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamid | 1987 |
Comparison of 1 + 5 DAT and 3 + 10 DAT followed by COAP or MAZE consolidation therapy in the treatment of acute myeloid leukemia: MRC ninth AML trial.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemothe | 1987 |
Results of induction and consolidation treatment with intermediate and high-dose ara-C and m-AMSA containing regimens in patients with primarily failed or relapsed acute leukemia and non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aminoacridines; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemoth | 1986 |
Randomized trial of high-dose cytarabine versus amsacrine in acute myelogenous leukemia in relapse: a Leukemia Intergroup Study.
Topics: Adolescent; Adult; Aged; Aminoacridines; Amsacrine; Antibiotics, Antineoplastic; Bone Marrow; Clinic | 1986 |
Amsacrine: a review.
Topics: Amsacrine; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemical | 1986 |
A new regimen of amsacrine with high-dose cytarabine is safe and effective therapy for acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; B | 1987 |
[AML-6 and AML-7 studies on the treatment of acute myelocytic leukemia. Cyclic alternating chemotherapy during remission, and induction of remission and survival of elderly patients].
Topics: Adult; Age Factors; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Antineoplastic Combined | 1985 |
95 other studies available for amsacrine and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Impact on Outcome of Minimal Residual Disease after Hematopoietic Stem Cell Transplantation with Fludarabine, Amsacrine, and Cytosine Arabinoside-Busulfan Conditioning: A Retrospective Monocentric Study.
Topics: Amsacrine; Busulfan; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, | 2023 |
Amsacrine-based induction therapy in AML patients with cardiac comorbidities: a retrospective single-center analysis.
Topics: Amsacrine; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Heart Disease | 2023 |
Combination of fludarabine, amsacrine, and cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia.
Topics: Adult; Amsacrine; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; C | 2013 |
Transplant-acquired food allergy (TAFA) following cord blood stem cell transplantation in two adult patients with haematological malignancies.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cord Bl | 2014 |
Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; C | 2016 |
Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Gr
Topics: Adolescent; Adult; Aged; Allografts; Amsacrine; Bone Marrow Transplantation; Busulfan; Cyclophospham | 2017 |
Poor-risk cytogenetics may be associated with inferior outcome after fludarabine, cytarabine, and amsacrine reduced intensity conditioning in patients with high-risk acute myeloid leukemia.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytogenetics; Female; | 2011 |
AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Aminoglycosides; Amsacrine; Antibodies, Monoclonal, Humanized; Antineoplastic Com | 2012 |
Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effective salvage therapy option for acute myeloid leukemia at first relapse.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Fema | 2013 |
Factors influencing outcome and incidence of long-term complications in children who underwent autologous stem cell transplantation for acute myeloid leukemia in first complete remission.
Topics: Adolescent; Amsacrine; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bone Ma | 2003 |
Comparison of BAVC to BuCy regimens in autologous stem cell transplantation for adult patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmus | 2004 |
Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distr | 2005 |
Usefulness of PKH fluorescent labelling to study leukemic cell proliferation with various cytostatic drugs or acetyl tetrapeptide--AcSDKP.
Topics: Amsacrine; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Br | 2005 |
The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients.
Topics: Adult; Aged; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boron | 2007 |
Addition of PTK787/ZK 222584 can lower the dosage of amsacrine to achieve equal amounts of acute myeloid leukemia cell death.
Topics: Amsacrine; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Syne | 2008 |
[Treatment of acute myeloid leukemia].
Topics: Adult; Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; | 1984 |
[Phase II study of AMSA in adults with acute therapy-refractory leukemias].
Topics: Adolescent; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Drug Evaluation; Humans; | 1983 |
[Combined therapy with AMSA and etoposide (VP 16-213) in refractory acute myeloid leukemia. A phase I study].
Topics: Aminoacridines; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dr | 1984 |
Case of refractory acute myeloblastic leukemia who achieved complete remission by a new anti-leukemic agent, 4'-(9-acridinylamino) methanesulfon-m-anisidide (AMSA).
Topics: Adult; Aminoacridines; Amsacrine; Antineoplastic Agents; Female; Humans; Leukemia, Myeloid, Acute | 1983 |
Amsacrine in refractory adult acute leukemia: a pilot study of the Southeastern Cancer Study Group.
Topics: Adolescent; Adult; Aged; Aminoacridines; Amsacrine; Bone Marrow; Drug Evaluation; Female; Humans; Hy | 1983 |
Phase II study of amsacrine gluconate in refractory leukemia.
Topics: Adult; Aged; Aminoacridines; Amsacrine; Drug Evaluation; Female; Gluconates; Humans; Lactates; Leuke | 1983 |
Prediction of complete remission in patients with refractory acute leukemia treated with AMSA.
Topics: Acute Disease; Adult; Aminoacridines; Amsacrine; Female; Humans; Leukemia; Leukemia, Lymphoid; Leuke | 1984 |
AMSA: a phase II trial in resistant and recurrent acute myelogenous leukemia.
Topics: Aminoacridines; Amsacrine; Drug Evaluation; Drug Resistance; Humans; Leukemia, Myeloid, Acute; Recur | 1984 |
m-AMSA: phase II trial in advanced lymphoma and leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Bone Marro | 1984 |
A non-clonogenic assay for the determination of the sensitivity of leukemic cells to chemotherapeutic agents.
Topics: Aclarubicin; Aminoacridines; Amsacrine; Antineoplastic Agents; Bone Marrow; Cell Division; Cell Surv | 1983 |
4'-(9-Acridinylamino) methanesulfon-m-anisidide (AMSA): a new drug effective in the treatment of adult acute leukemia.
Topics: Adolescent; Adult; Aged; Aminoacridines; Amsacrine; Bone Marrow; Dose-Response Relationship, Drug; D | 1980 |
Amsacrine (AMSA).
Topics: Aminoacridines; Amsacrine; Animals; Antineoplastic Agents; Breast Neoplasms; Dogs; Dose-Response Rel | 1980 |
Self-renewal capacity of leukemic blast progenitor cells.
Topics: Aminoacridines; Amsacrine; Cell Division; Clone Cells; Cytarabine; Dose-Response Relationship, Drug; | 1981 |
A phase I and II study of m-AMSA in acute leukaemia.
Topics: Adolescent; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Child; Child, Preschool; | 1981 |
Evaluation of AMSA in previously treated patients with acute leukemia: results of therapy in 109 adults.
Topics: Acute Disease; Aminoacridines; Amsacrine; Antineoplastic Agents; Dose-Response Relationship, Drug; H | 1982 |
Phase I and II study of AMSA in childhood tumours.
Topics: Adolescent; Aminoacridines; Amsacrine; Antineoplastic Agents; Child; Child, Preschool; Drug Administ | 1982 |
Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia.
Topics: Amsacrine; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carrier Proteins; Daunorubicin; | 1994 |
Interactions between cladribine (2-chlorodeoxyadenosine) and standard antileukemic drugs in primary cultures of human tumor cells from patients with acute myelocytic leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Agents; Cladribine; Cytarabine | 1994 |
Treatment of relapsed acute myeloid leukemia using GM-CSF before intensive chemotherapy.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Mar | 1993 |
Treatment of relapsing and refractory adult acute myeloid leukemia according to in vitro clonogenic leukemic cell drug sensitivity.
Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Et | 1993 |
Intensive induction and consolidation chemotherapy in a young woman with acute myeloid leukemia and severe chronic renal failure.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Contraindications; Cytarabine; Dau | 1996 |
Topoisomerase II inhibitors induce DNA double-strand breaks at a specific site within the AML1 locus.
Topics: Amsacrine; Antineoplastic Agents; Base Sequence; Cell Line; Dactinomycin; DNA Damage; DNA, Neoplasm; | 1997 |
In vitro cytotoxic drug activity and in vivo pharmacokinetics in childhood acute myeloid leukemia.
Topics: Amsacrine; Antineoplastic Agents; Blast Crisis; Bone Marrow; Cell Survival; Child; Cytarabine; Doxor | 1999 |
Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome.
Topics: Amsacrine; Anthracyclines; Antineoplastic Agents; Busulfan; Cell Survival; Child; Child, Preschool; | 2002 |
Multidrug resistance (MDR) gene expression in acute non lymphoblastic leukemia: sequential analysis.
Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transpo | 1992 |
Survival in 91 adults with acute myelogenous leukaemia treated with 1-6 intensive courses of chemotherapy.
Topics: Actuarial Analysis; Adolescent; Adult; Age Factors; Amsacrine; Antineoplastic Combined Chemotherapy | 1992 |
Double intensification with amsacrine/high dose ara-C and high dose chemotherapy with autologous bone marrow transplantation produces durable remissions in acute myelogenous leukemia.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplanta | 1990 |
[Intensification chemotherapy followed by allogenieic and autologous bone marrow transplantation in acute non-lymphoblastic leukemia in children].
Topics: Adolescent; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; | 1991 |
The amsacrine story: will it change the FDA policy?
Topics: Amsacrine; Humans; Legislation, Drug; Leukemia, Myeloid, Acute; United States; United States Food an | 1991 |
Amsacrine is safe and effective therapy for patients with myocardial dysfunction and acute leukemia.
Topics: Amsacrine; Cardiac Output, Low; Cytarabine; Drug Therapy, Combination; Humans; Leukemia; Leukemia, M | 1991 |
[Extravasation of cytostatics. Example of a severe complication from the use of long-term central venous catheters].
Topics: Amsacrine; Antineoplastic Agents; Catheterization, Central Venous; Equipment Failure; Extravasation | 1991 |
Doxorubicin and m-AMSA induced DNA damage in blast cells from AML patients.
Topics: Adult; Aged; Amsacrine; DNA Damage; DNA, Single-Stranded; Doxorubicin; Female; Humans; Leukemia, Mye | 1991 |
Pharmacokinetics of continuous-infusion amsacrine and teniposide for the treatment of relapsed childhood acute nonlymphocytic leukemia.
Topics: Adolescent; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Huma | 1991 |
Resistance to 4-(9-acridinylamino) methanesulphon-m-anisidide (m-AMSA) in human myeloid leukaemia.
Topics: Amsacrine; Cell Line; Cell Survival; DNA Damage; DNA, Neoplasm; Drug Resistance; Humans; Leukemia, M | 1990 |
Cellular ara-CTP pharmacokinetics, response, and karyotype in newly diagnosed acute myelogenous leukemia.
Topics: Amsacrine; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Chromosome Deletion; Chromosom | 1990 |
Double intensive consolidation chemotherapy (ICC) for acute myeloid leukemia.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmu | 1990 |
Treatment of recurrent acute myelogenous leukaemia at a single centre over a 10-year period.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplant | 1990 |
Prognostic value of dysmyelopoietic features in de novo acute myeloid leukaemia: a report on 132 patients.
Topics: Adolescent; Adult; Amsacrine; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Prot | 1990 |
BAVC regimen and autologous bone marrow transplantation in patients with acute myelogenous leukemia in second remission.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplant | 1990 |
Intermediate-dose cytosine arabinoside and amsacrine. An effective regimen with low toxicity in refractory acute nonlymphocytic leukemia.
Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; | 1990 |
Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia.
Topics: Adult; Age Factors; Amsacrine; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Pro | 1990 |
The role of peripheral blood stem cells as rescue after myeloablative therapy.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Combined Modality Ther | 1989 |
Amsacrine, cytarabine and etoposide in the treatment of bad prognosis acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemotherapy Protocol | 1989 |
A special role for amsacrine in the treatment of acute leukemia.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Myeloid, Acute; Precurs | 1989 |
Autologous bone marrow transplantation in patients with AML in second complete remission (CR).
Topics: Adolescent; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; | 1989 |
[4'-(9-acridinylamino)-methanesulfon-m-aniside (AMSA) combination salvage therapy in refractory acute non-lymphocytic leukemia in adults].
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daun | 1989 |
Effective reinduction therapy for childhood acute nonlymphoid leukemia using simultaneous continuous infusions of teniposide and amsacrine.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Child; C | 1989 |
Necrotizing fasciitis of the vulva during chemotherapy.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Fasciitis; Female; Hum | 1989 |
Effect of polyamine depletion by alpha-difluoromethylornithine or (2R,5R)-6-heptyne-2,5-diamine on drug-induced topoisomerase II-mediated DNA cleavage and cytotoxicity in human and murine leukemia cells.
Topics: Alkynes; Amsacrine; Animals; Antineoplastic Agents; Cell Line; Cell Survival; Diamines; DNA; DNA Dam | 1987 |
Protein kinase C phosphorylates topoisomerase II: topoisomerase activation and its possible role in phorbol ester-induced differentiation of HL-60 cells.
Topics: Aminoacridines; Amsacrine; Animals; Cell Differentiation; Cell Line; DNA Topoisomerases, Type II; Dr | 1986 |
In vitro toxicity and DNA cleaving capacity of benzisoquinolinedione (nafidimide; NSC 308847) in human leukemia.
Topics: Adenine; Amsacrine; Cell Line; Clone Cells; DNA; DNA Topoisomerases, Type I; Doxorubicin; Electropho | 1987 |
The interaction between nuclear topoisomerase II activity from human leukemia cells, exogenous DNA, and 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) or 4-(4,6-O-ethylidene-beta-D-glucopyranoside) (VP-16) indicates the sensitivity of the cells t
Topics: Amsacrine; Animals; Cell Line; Cell Nucleus; Crithidia; DNA; DNA Topoisomerases, Type II; Humans; Ki | 1987 |
Intermediate and high dose Ara-C and m-AMSA for remission induction and consolidation treatment of patients with acute myeloid leukemia: an EORTC Leukemia Cooperative Group phase II study.
Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; | 1988 |
Continuous-infusion amsacrine in patients with refractory acute myelogenous leukemia.
Topics: Adult; Amsacrine; Diagnosis-Related Groups; Humans; Leukemia, Myeloid, Acute | 1987 |
Comparison of results of salvage therapy in adult acute myelogenous leukemia.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Doxorubi | 1987 |
[Combination of AMSA-high dose cytosine arabinoside in acute leukemia].
Topics: Adolescent; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; | 1985 |
Results of induction and consolidation treatment with intermediate and high-dose cytosine arabinoside and m-Amsa of patients with poor-risk acute myelogenous leukaemia.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Sc | 1988 |
Factor X deficiency during treatment of relapsed acute myeloid leukaemia with amsacrine.
Topics: Adult; Amsacrine; Blood Transfusion; Drug Therapy, Combination; Etoposide; Factor IX; Factor X; Fact | 1988 |
Autologous bone marrow transplantation for patients with acute myelogenous leukemia in complete remission.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; | 1987 |
Efficacy and clinical cross-resistance of a new combination therapy (AMSA/VP16) in previously treated patients with acute nonlymphocytic leukemia.
Topics: Adolescent; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; | 1986 |
Acute promyelocytic leukemia. M.D. Anderson Hospital experience.
Topics: Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Cytara | 1986 |
Loss of viability and induction of DNA damage in human leukemic myeloblasts and lymphocytes by m-AMSA.
Topics: Aminoacridines; Amsacrine; Cell Cycle; Cell Line; Cell Survival; DNA; DNA Repair; DNA, Neoplasm; Dos | 1986 |
Treatment of acute leukaemia with m-AMSA in combination with cytosine arabinoside.
Topics: Aged; Amsacrine; Chemical and Drug Induced Liver Injury; Cytarabine; Female; Gastrointestinal Diseas | 1986 |
Development and characterization of a human myelogenous leukemia cell line resistant to 4'-(9-acridinylamino)-3-methanesulfon-m-anisidide.
Topics: Amsacrine; Cell Division; Cell Line; Doxorubicin; Drug Resistance; Karyotyping; Kinetics; Leukemia, | 1987 |
AMSA: in vivo log cell kill for leukemic clonogenic cells versus toxicity for normal hemopoietic stem cells in a rat model for human acute myelocytic leukemia (BNML).
Topics: Amsacrine; Animals; Clone Cells; Colony-Forming Units Assay; Disease Models, Animal; Hematopoietic S | 1986 |
m-AMSA and VP-16 combinations in the treatment of acute myeloid leukemia.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Leukemia, Myeloid, Acu | 1987 |
High-dose busulfan and amsacrine with autologous bone marrow rescue in patients with acute myeloid leukemia in first remission.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Humans; Leukemia, Myelo | 1987 |
Prognostic value of in vitro uptake and retention of cytosine arabinoside in acute myelogenous leukemia.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Daunorubicin; Hu | 1987 |
Intensive treatment of acute leukemia in adults 70 years of age and older.
Topics: Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daun | 1987 |
Phase II study of amsacrine and high-dose cytarabine for resistant acute myelogenous leukemia.
Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation; | 1987 |
Effective remission induction in children with recurrent acute myeloid leukemia by mAMSA, Ara-C, and VP 16.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Etoposide; Female; Hum | 1987 |
Remission of rheumatoid arthritis with the successful treatment of acute myelogenous leukemia with cytosine arabinoside, daunorubicin, and m-AMSA.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Arthritis, Rheumatoid; Cytarabine; Daunor | 1987 |
Pulmonary complications of cytosine-arabinoside therapy: radiographic findings.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Humans; Leukemia, | 1987 |
Pharmacokinetics of amsacrine in patients receiving combined chemotherapy for treatment of acute myelogenous leukemia.
Topics: Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 1985 |
Intermediate and high-dose ARA-C and m-AMSA (or daunorubicin) as remission and consolidation treatment for patients with relapsed acute leukaemia and lymphoblastic non-Hodgkin lymphoma.
Topics: Adolescent; Adult; Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytara | 1985 |
Amsacrine and etoposide induced paralytic ileus in a patient with acute myelomonocytic leukemia.
Topics: Aged; Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; | 1985 |
[Treatment of acute myeloid leukemia with amsacrine and high-dose cytosine arabinoside: a phase II trial].
Topics: Adult; Aminoacridines; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc | 1985 |
Modulation of cytosine arabinoside (ara-C) and high-dose ara-C in acute leukemia.
Topics: Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistan | 1985 |
[Experiences with HD-Ara C treatment in leukemia patients].
Topics: Acute Disease; Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine | 1985 |
[AMSA/etoposide (VP 16-213). A phase I/II study in refractory acute myeloid leukemia].
Topics: Aminoacridines; Aminoglutethimide; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemoth | 1985 |